[
  {
    "ts": null,
    "headline": "EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer",
    "summary": "Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.",
    "url": "https://finnhub.io/api/news?id=a5f86313bb6bccdd44acd7bc9d15de3a53dee60e8fa4a6bfa6e79563ceae3327",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732813320,
      "headline": "EC Approves NVS' Kisqali for a Broad Population in Early Breast Cancer",
      "id": 131694993,
      "image": "https://media.zenfs.com/en/zacks.com/f166d65586ad9d3236a947b8d942f4c9",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novartis wins EC approval for Kisqali in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence.",
      "url": "https://finnhub.io/api/news?id=a5f86313bb6bccdd44acd7bc9d15de3a53dee60e8fa4a6bfa6e79563ceae3327"
    }
  },
  {
    "ts": null,
    "headline": "Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?",
    "summary": "Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion.  Why is Eli Lilly stock struggling of late?  Eli Lilly has been a fantastic growth stock to own in recent years.",
    "url": "https://finnhub.io/api/news?id=ab7ab77f70256a806aa0c22d463cf0d4a47f5f196859581780430cd5657ffcab",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732797000,
      "headline": "Down More Than 20% From Its High, Is Now the Time to Buy Eli Lilly Stock?",
      "id": 131685807,
      "image": "https://g.foolcdn.com/editorial/images/798828/businessman-with-a-chart-looking-at-his-computer.jpg",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of nearly $700 billion.  Why is Eli Lilly stock struggling of late?  Eli Lilly has been a fantastic growth stock to own in recent years.",
      "url": "https://finnhub.io/api/news?id=ab7ab77f70256a806aa0c22d463cf0d4a47f5f196859581780430cd5657ffcab"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Forty Fund Q3 2024 Commentary",
    "summary": "The Janus Henderson Forty Fund returned 5.23% and the Russell 1000Â® Growth Index returned 3.19% for Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=76fdf961d575a4ee1b622b8fbf13422d035e2baaccc3f305144d523ed600f266",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732794000,
      "headline": "Janus Henderson Forty Fund Q3 2024 Commentary",
      "id": 131687381,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/695477748/image_695477748.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Janus Henderson Forty Fund returned 5.23% and the Russell 1000Â® Growth Index returned 3.19% for Q3 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=76fdf961d575a4ee1b622b8fbf13422d035e2baaccc3f305144d523ed600f266"
    }
  },
  {
    "ts": null,
    "headline": "The Winners And Losers Of Biden's Plans To Expand Coverage Of Weight-Loss Drugs",
    "summary": "US President Joe Biden wants to expand the governmentâs coverage of weight-loss drugs. Click to read.",
    "url": "https://finnhub.io/api/news?id=bfad731a5165d2b7e12d325f024f7bbe8c2d7347007686cad01eb1960a16c2e3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732785240,
      "headline": "The Winners And Losers Of Biden's Plans To Expand Coverage Of Weight-Loss Drugs",
      "id": 131685031,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1406728374/image_1406728374.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "US President Joe Biden wants to expand the governmentâs coverage of weight-loss drugs. Click to read.",
      "url": "https://finnhub.io/api/news?id=bfad731a5165d2b7e12d325f024f7bbe8c2d7347007686cad01eb1960a16c2e3"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Concentrated Growth Managed Account Q3 2024 Commentary",
    "summary": "The Janus Henderson Concentrated Growth Managed Account Portfolio returned 4.87% \n(gross) for Q3 2024. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=8850d4c13507d94fb162193ca20fc2d146b48a64b92968a47914d40e5d42996f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732784700,
      "headline": "Janus Henderson Concentrated Growth Managed Account Q3 2024 Commentary",
      "id": 131684895,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1357662559/image_1357662559.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Janus Henderson Concentrated Growth Managed Account Portfolio returned 4.87% \n(gross) for Q3 2024. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=8850d4c13507d94fb162193ca20fc2d146b48a64b92968a47914d40e5d42996f"
    }
  },
  {
    "ts": null,
    "headline": "Janus Henderson Global Life Sciences Fund Q3 2024 Commentary",
    "summary": "Janus Henderson Global Life Sciences Fund returned 5.39% and the MSCI World Health Care IndexSM returned 5.70%. Read more here.",
    "url": "https://finnhub.io/api/news?id=6f33758f49e72ec36ead70f5b29bda23bdb6b5a987e6dc45a309c6604763ed75",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732784100,
      "headline": "Janus Henderson Global Life Sciences Fund Q3 2024 Commentary",
      "id": 131684758,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1488432016/image_1488432016.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Janus Henderson Global Life Sciences Fund returned 5.39% and the MSCI World Health Care IndexSM returned 5.70%. Read more here.",
      "url": "https://finnhub.io/api/news?id=6f33758f49e72ec36ead70f5b29bda23bdb6b5a987e6dc45a309c6604763ed75"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)",
    "summary": "Eli Lillyâs strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull back amid market concerns.",
    "url": "https://finnhub.io/api/news?id=1771bf257d4a23595007de520d5655dcad755a028ba8115c50322de6ddec0b28",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732782600,
      "headline": "Eli Lilly: An Early Christmas Present Has Just Arrived (Rating Upgrade)",
      "id": 131684568,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lillyâs strong position in GLP-1 drugs is overlooked by the market. Find out why LLY stock is a buy even as others pull back amid market concerns.",
      "url": "https://finnhub.io/api/news?id=1771bf257d4a23595007de520d5655dcad755a028ba8115c50322de6ddec0b28"
    }
  }
]